ArticleJournal of neuro-oncology2023
Survival after resection of brain metastasis: impact of synchronous versus metachronous metastatic disease.
Article in Journal of neuro-oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 14 citations in OpenAlex.
- Risk stratification for unfavorable outcome after resection of selected brain metastases in patients with multiple brain metastases.Journal of neuro-oncology · 2026Article
- Identifying Prognostic Factors in Brain Metastasis Patients Using MRI Morphological Features: A Machine Learning and Survival Analysis Approach.Diagnostics (Basel, Switzerland) · 2026Article
- Surgical resection for multiple brain metastases: a systematic review and meta-analysis of functional and survival outcomes.Medicine and pharmacy reports · 2025Review
- Comparative survival outcome of synchronous and metachronous brain metastasis from colorectal cancer: A meta‑analysis.Oncology letters · 2025Article
- Validation of a prognostic scoring system for brain metastases with synchronous detection of primary cancers at initial consultation.Frontiers in oncology · 2025Article
- Brain metastases: Comparing clinical radiological differences in patients with lung and breast cancers treated with surgery.World neurosurgery: X · 2024Article
- Patients with Leptomeningeal Carcinomatosis and Hydrocephalus-Feasibility of Combined Ventriculoperitoneal Shunt and Reservoir Insertion for Intrathecal Chemotherapy.Current oncology (Toronto, Ont.) · 2024Article
- Synchronous versus metachronous spinal metastasis: a comparative study of survival outcomes following neurosurgical treatment.Journal of cancer research and clinical oncology · 2024Article
- Analysis of prognostic factors and the role of epilepsy in neurosurgical patients with brain metastases.Surgical neurology international · 2024Article
- Outcome assessment of intraoperative radiotherapy for brain metastases: results of a prospective observational study with comparative matched-pair analysis.Journal of neuro-oncology · 2023Observational
- Survival in patients undergoing surgical resection for brain metastasis from lung cancer and utility of different prognostic scales.Neurosurgical review · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePatients with brain metastasis (BM) from solid tumors are in an advanced stage of cancer. BM may occur during a known oncological disease (metachronous BM) or be the primary manifestation of previously unknown cancer (synchronous BM). The time of diagnosis might decisively impact patient prognosis and further treatment stratification. In the present study, we analyzed the prognostic impact of synchronous versus (vs.) metachronous BM occurrence following resection of BM.
methodsBetween 2013 and 2018, 353 patients had undergone surgical therapy for BM at the authors' neuro-oncological center. Survival stratification calculated from the day of neurosurgical resection was performed for synchronous vs. metachronous BM diagnosis.
resultsNon-small-cell lung carcinoma (NSCLC) was the most common tumor entity of primary site (43%) followed by gastrointestinal cancer (14%) and breast cancer (13%). Synchronous BM occurrence was present in 116 of 353 patients (33%), metachronous BM occurrence was present in 237 of 353 patients (67%). NSCLC was significantly more often diagnosed via resection of the BM (56% synchronous vs. 44% metachronous situation, p = 0.0001). The median overall survival for patients with synchronous BM diagnosis was 12 months (95% confidence interval (CI) 7.5-16.5) compared to 13 months (95% CI 9.6-16.4) for patients with metachronous BM diagnosis (p = 0.97).
conclusionsThe present study indicates that time of BM diagnosis (synchronous vs. metachronous) does not significantly impact patient survival following surgical therapy of BM. These results suggest that the indication for neurosurgical BM resection should be made regardless of a synchronous or a metachronous time of BM occurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.